Teva Pharmaceutical Industries Limited Stock TEL AVIV STOCK EXCHANGE
Stocks
IL0006290147
Pharmaceuticals
OTC Markets Traded| Market Cap | 40.56B 0 35.2B 32.96B 30.15B 56.92B 3,864B 57.67B 386B 151B 1,931B 152B 149B 6,426B | P/E 2026 * |
46.7x | P/E 2027 * | 19.1x |
|---|---|---|---|---|---|
| Enterprise Value | 52.44B 0 45.51B 42.61B 38.98B 73.59B 4,996B 74.55B 499B 196B 2,496B 197B 193B 8,307B | EV / Sales 2026 * |
3.16x | EV / Sales 2027 * | 2.84x |
| Free-Float |
88.59% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Teva Pharmaceutical Industries Limited
| 1 day | -3.96% |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 2022-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 2019-12-21 |
Matthew Shields
COO | Chief Operating Officer | 52 | 2024-06-02 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 2008-12-31 |
Sol Barer
CHM | Chairman | 78 | 2017-02-05 |
Rosemary Crane
BRD | Director/Board Member | 65 | 2015-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.96% | -3.32% | - | - | 40.56B | |
| +1.89% | +3.20% | +59.70% | +165.18% | 1,062B | |
| -0.24% | +0.45% | +50.64% | +52.02% | 619B | |
| -0.95% | -5.26% | +24.23% | +65.08% | 431B | |
| +2.08% | +5.35% | +49.54% | +40.65% | 358B | |
| +0.96% | -0.19% | +35.80% | +40.63% | 293B | |
| +1.30% | -4.97% | +9.63% | +10.27% | 247B | |
| -0.73% | +4.44% | +42.22% | +66.41% | 219B | |
| +4.65% | -0.15% | -0.91% | -43.92% | 200B | |
| -0.68% | -0.32% | +18.66% | +66.32% | 162B | |
| Average | +0.16% | -1.90% | +32.17% | +51.40% | 399.14B | |
| Weighted average by Cap. | +0.12% | -0.83% | +41.18% | +78.30% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.58B 0 14.39B 13.47B 12.33B 23.27B 1,580B 23.57B 158B 61.86B 789B 62.26B 60.91B 2,627B | 17.3B 0 15.02B 14.06B 12.86B 24.28B 1,648B 24.6B 165B 64.56B 824B 64.97B 63.56B 2,741B |
| Net income | 1.14B 0 990M 927M 848M 1.6B 109B 1.62B 10.84B 4.25B 54.28B 4.28B 4.19B 181B | 2.34B 0 2.03B 1.9B 1.74B 3.28B 223B 3.32B 22.22B 8.72B 111B 8.77B 8.58B 370B |
| Net Debt | 11.88B 0 10.31B 9.65B 8.83B 16.67B 1,131B 16.89B 113B 44.31B 565B 44.6B 43.63B 1,882B | 8.61B 0 7.47B 7B 6.4B 12.08B 820B 12.24B 81.86B 32.13B 410B 32.33B 31.63B 1,364B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
